Antengene Unveils Breakthrough Results from TORCH-2 Trial of ATG-008: A Promising mTORC1/2 Inhibitor to be Discussed at 2023 ASCO

Antengene Corporation Limited (SEHK: 6996.HK), a pioneering biopharmaceutical company dedicated to developing groundbreaking treatments for cancer, is proud to announce the results of their Phase I/II TORCH-2 study will be presented at the American Society for Clinical Oncology Annual Meeting (ASCO 2023) in Chicago.

From June 2nd to 6th, medical experts from around the world will gather at McCormick Place Convention Center to learn about the latest advancements in cancer research – including Antengene’s TORCH-2 study.

The TORCH-2 study is a groundbreaking clinical trial that seeks to further explore the potential of ATG-008, a novel mTORC1/2 inhibitor, when used in tandem with the anti-PD-L1 antibody, toripalimab. This open-label dose escalation and expansion study is being conducted to assess the efficacy of this combination therapy in treating advanced solid tumors.

At the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in 2023, Antengene will present the results of the TORCH-2 study, which suggests that combining ATG-008 with an immune checkpoint inhibitor could be a more effective and durable way to control tumors.

This is due to the powerful role that the mTOR signaling pathway plays in the biology of immune cells. Dr. Amily Zhang, Antengene’s Chief Medical Officer, is excited to share these findings with the oncology community.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is dedicated to making a difference for people with cancer around the globe. As a leading commercial-stage R&D-driven biopharmaceutical company, Antengene is committed to discovering, developing, manufacturing and commercializing innovative first-in-class/best-in-class therapeutics, with the goal of helping cancer patients beyond borders.

Since 2017, Antengene has made tremendous strides in oncology, developing a pipeline of nine assets at various stages from clinical to commercial and spanning six with global rights and three with rights for the APAC region.

In addition, the company has obtained 28 investigational new drug (IND) approvals across the U.S. and Asia, as well as submitted 9 new drug applications (NDAs) in multiple Asia Pacific markets. Among them, XPOVIO® (selinexor) has already been approved in Mainland of China, Taiwan,China, South Korea, Singapore, and Australia.

Leave a Comment